Annual report pursuant to Section 13 and 15(d)

Acquisitions (Details)

v3.24.1
Acquisitions (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jun. 21, 2022
Dec. 31, 2023
Dec. 31, 2022
Oct. 11, 2022
Acquisition [Line Items]        
Common stock acquisition shares 163,044 135,000 163,044  
Warrants acquired shared 50,000 50,000    
Exercise price per share (in Dollars per share) $ 37.6 $ 37.6    
Aggregate fair value (in Dollars) $ 700,000      
Asset acquisition description   (i) an aggregate of 135,000 shares of Common Stock, (ii) an aggregate of 50,000 warrants to purchase shares of Common Stock at an exercise price of $37.60 per share, which may be exercised on a cashless basis, for a period of five years commencing on the date of issuance, (iii) a cash payment in the amount of $1,050,000, (iv) the right to certain milestone payments in an amount up to $5,000,000, and (v) the right to contingent earn-out payments ranging from 3% to 5% of net sales of the drug depending on the amount of such net sales in the applicable measurement period.    
Additional shares of common stock   5,625    
Asset Acquisition [Member]        
Acquisition [Line Items]        
Common stock acquisition shares   67,500    
Business Combination [Member]        
Acquisition [Line Items]        
Outstanding membership interests percentage 100.00%     100.00%
Business Combination market price (in Dollars per share) $ 20.2      
Exercise price per share (in Dollars per share) $ 37.6      
Acquisition date (in Dollars) $ 5      
Aggregate fair value (in Dollars)   $ 311,000